

Caitlin R Early

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4390705/publications.pdf>

Version: 2024-02-01

60
papers

1,687
citations

430442

18
h-index

301761

39
g-index

60
all docs

60
docs citations

60
times ranked

1831
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical experience with the BCL-2 inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. <i>American Journal of Hematology</i> , 2018, 93, 401-407.	2.0	336
2	10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e724-e736.	2.2	201
3	Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2021, 11, 25.	2.8	85
4	Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. <i>Haematologica</i> , 2021, 106, 894-898.	1.7	80
5	Outcomes of TP53 mutant acute myeloid leukemia with decitabine and venetoclax. <i>Cancer</i> , 2021, 127, 3772-3781.	2.0	80
6	Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole. <i>Clinical Infectious Diseases</i> , 2018, 67, 1610-1613.	2.9	73
7	Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 212-218.	0.2	71
8	Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. <i>American Journal of Hematology</i> , 2021, 96, 282-291.	2.0	59
9	Treating Leukemia in the Time of COVID-19. <i>Acta Haematologica</i> , 2021, 144, 132-145.	0.7	57
10	Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 1876-1883.	2.5	56
11	Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study. <i>Clinical Infectious Diseases</i> , 2021, 72, 1755-1763.	2.9	48
12	A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2018, 132, 465-465.	0.6	48
13	Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 3848-3857.	0.8	41
14	Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. <i>Cancer</i> , 2021, 127, 2489-2499.	2.0	34
15	Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients. <i>Mycoses</i> , 2019, 62, 81-86.	1.8	31
16	Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management. <i>Cancer</i> , 2020, 126, 1152-1160.	2.0	29
17	Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis. <i>Cancer</i> , 2021, 127, 4213-4220.	2.0	24
18	Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study. <i>Blood Cancer Journal</i> , 2021, 11, 60.	2.8	22

#	ARTICLE	IF	CITATIONS
19	Decitabine and venetoclax for IDH1/2 mutated acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, E154-E157.	2.0	19
20	Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 2018, 132, 286-286.	0.6	19
21	PEGging down risk factors for peg-asparaginase hepatotoxicity in patients with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 617-624.	0.6	18
22	A Phase II Study of Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2020, 136, 7-9.	0.6	17
23	Implementing a Method for Evaluating Patient-Reported Outcomes Associated With Oral Oncolytic Therapy. <i>Journal of Oncology Practice</i> , 2017, 13, e395-e400.	2.5	16
24	Comparison of Mold Active Triazoles as Primary Antifungal Prophylaxis in Patients With Newly Diagnosed Acute Myeloid Leukemia in the Era of Molecularly Targeted Therapies. <i>Clinical Infectious Diseases</i> , 2022, 75, 1503-1510.	2.9	16
25	Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin. <i>Future Oncology</i> , 2017, 13, 2233-2242.	1.1	15
26	Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial. <i>Blood</i> , 2019, 134, 2637-2637.	0.6	15
27	Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study. <i>Blood</i> , 2020, 136, 15-17.	0.6	14
28	Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, 914-924.	2.0	13
29	Safety and Efficacy of Blinatumomab in Patients with Central Nervous System (CNS) Disease: A Single Institution Experience. <i>Blood</i> , 2018, 132, 2702-2702.	0.6	13
30	L-carnitine and Vitamin B Complex for the Treatment of Pegasparaginase-induced Hyperbilirubinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e191-e195.	0.2	12
31	Clinical and molecular characterization of myeloid sarcoma without medullary leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 3402-3410.	0.6	12
32	Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2640-2640.	0.6	12
33	Outcomes of TP53-Mutant Acute Myeloid Leukemia with Venetoclax and Decitabine. <i>Blood</i> , 2020, 136, 33-36.	0.6	12
34	Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 2184-2192.	0.6	10
35	Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 645-645.	0.6	9
36	Venetoclax, FLT3 Inhibitor and Decitabine in FLT3mut Acute Myeloid Leukemia: Subgroup Analysis of a Phase II Trial. <i>Blood</i> , 2020, 136, 53-55.	0.6	8

#	ARTICLE	IF	CITATIONS
37	Updated Results from a Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 3400-3400.	0.6	8
38	Prolonged voriconazole treatment in a patient with chronic lymphocytic leukemia resulting in a litany of chronic overlapping toxicities. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 747-753.	0.5	7
39	Cell cycle inhibitors for the treatment of acute myeloid leukemia: a review of phase 2 & 3 clinical trials. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 491-499.	1.0	6
40	Benefits of a concentrated teaching rotation: Perspectives of pharmacy residents and faculty. <i>Currents in Pharmacy Teaching and Learning</i> , 2017, 9, 4-8.	0.4	4
41	Complexity of chronic-phase CML management after failing a second-generation TKI. <i>Leukemia and Lymphoma</i> , 2020, 61, 776-787.	0.6	4
42	Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. <i>American Journal of Hematology</i> , 2022, 97, 885-894.	2.0	4
43	PET-CT in AML-related hemophagocytic lymphohistiocytosis. <i>Leukemia and Lymphoma</i> , 2018, 59, 1486-1489.	0.6	3
44	The face of remission induction. <i>British Journal of Haematology</i> , 2020, 188, 101-115.	1.2	3
45	Ten-Day Decitabine with Venetoclax Versus Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia: A Propensity Score Matched Analysis. <i>Blood</i> , 2020, 136, 30-33.	0.6	3
46	Breakthrough Invasive Fungal Infections (bIFI) Are Uncommon in Patients with Newly Diagnosed Acute Leukemia Receiving Primary Antifungal Prophylaxis. <i>Blood</i> , 2020, 136, 31-32.	0.6	3
47	Phase II Study of Venetoclax Added to Cladribine (CLAD) and Low Dose AraC (LDAC) Alternating with 5-Azacytidine (AZA) in Older and Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2021, 138, 367-367.	0.6	3
48	Breakthrough Invasive Fungal Infections (bIFI) in Adult Patients with Leukemia Receiving Isavuconazole (ISA). <i>Open Forum Infectious Diseases</i> , 2017, 4, S718-S718.	0.4	2
49	SOHO State of the Art Update and Next Questions: Advances in the Treatment of Adult Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 471-479.	0.2	2
50	Treating Rosai-Dorfman disease and RAS-associated autoimmune leucoproliferative disorder with malignant transformation. <i>British Journal of Haematology</i> , 2021, 192, 667-671.	1.2	2
51	Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine. <i>Leukemia and Lymphoma</i> , 2021, , 1-5.	0.6	2
52	Pattern of Immune-Mediated Toxicities in Patients with Myelodysplastic Syndrome (MDS) Treated with Nivolumab and Ipilimumab. <i>Blood</i> , 2018, 132, 4367-4367.	0.6	2
53	Urgent Cytoreductive Chemotherapy for Newly Diagnosed Patients with AML Is Safe and Feasible and Facilitates Enrollment on Investigational Clinical Trials. <i>Blood</i> , 2020, 136, 2-4.	0.6	2
54	Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective Study. <i>Blood</i> , 2018, 132, 2674-2674.	0.6	1

#	ARTICLE	IF	CITATIONS
55	Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Updated Results of a Phase II Trial. <i>Blood</i> , 2021, 138, 1270-1270.	0.6	1
56	Clinical Experience of Venetoclax Combinations for Relapsed/Refractory Myeloid Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S4-S5.	0.2	0
57	Blinatumomab for the treatment of acute lymphoblastic leukemia: an update. <i>Expert Opinion on Orphan Drugs</i> , 2019, 7, 41-46.	0.5	0
58	Optimizing patient selection for treatment-free remission. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1220-1224.	0.5	0
59	Utility of Leucovorin Rescue in Patients with Acute Lymphoblastic Leukemia (ALL) Treated with the Mini-Hypercvd Regimen. <i>Blood</i> , 2018, 132, 1417-1417.	0.6	0
60	Minimal or Measurable Residual Disease in Acute Lymphoblastic Leukemia. <i>Hematologic Malignancies</i> , 2021, , 205-218.	0.2	0